These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Power of the two one-sided tests procedure in bioequivalence. Phillips KF J Pharmacokinet Biopharm; 1990 Apr; 18(2):137-44. PubMed ID: 2348380 [TBL] [Abstract][Full Text] [Related]
63. Controversy. II: Bioequivalence as an indicator of therapeutic equivalence: modeling the theoretic influence of bioinequivalence on single-dose drug effect. Olson SC; Eldon MA; Toothaker RD; Ferry JJ; Colburn WA J Clin Pharmacol; 1987; 27(5):342-5. PubMed ID: 3693579 [No Abstract] [Full Text] [Related]
64. Connections between average and individual bioequivalence. Munk A Stat Med; 2000 Oct; 19(20):2843-54. PubMed ID: 11033579 [TBL] [Abstract][Full Text] [Related]
65. Sample size determination for the two one-sided tests procedure in bioequivalence. Liu JP; Chow SC J Pharmacokinet Biopharm; 1992 Feb; 20(1):101-4. PubMed ID: 1588502 [No Abstract] [Full Text] [Related]
67. Incurred sample reanalysis in bioequivalence studies for abbreviated new drug applications. Subramaniam S; Stier E; Davit BM Bioanalysis; 2014; 6(24):3349-54. PubMed ID: 25534791 [No Abstract] [Full Text] [Related]
68. Update to the PhRMA perspective on population and individual bioequivalence. Barrett JS; Batra V; Chow A; Cook J; Gould AL; Heller AH; Lo MW; Patterson SD; Smith BP; Stritar JA; Vega JM; Zariffa N J Clin Pharmacol; 2000 Jun; 40(6):571-2. PubMed ID: 10868306 [No Abstract] [Full Text] [Related]
69. Determination of in vivo bioequivalence. Jackson AJ Pharm Res; 2002 Mar; 19(3):227-8. PubMed ID: 11934226 [TBL] [Abstract][Full Text] [Related]
70. Bayesian approach to bioequivalence assessment: an example. Fluehler H; Grieve AP; Mandallaz D; Mau J; Moser HA J Pharm Sci; 1983 Oct; 72(10):1178-81. PubMed ID: 6644568 [TBL] [Abstract][Full Text] [Related]
71. Equivalence testing for similarity in bioassays using bioequivalence criteria on the relative bioactivity. Baljé-Volkers C; Mzolo T; Talens E; IJzerman-Boon P; Van den Heuvel E Pharm Stat; 2018 Feb; 17(1):12-24. PubMed ID: 29110389 [TBL] [Abstract][Full Text] [Related]
72. Definition of individual bioequivalence: occasion-to-occasion versus mean switchability. Kimanani EK Stat Med; 2000 Oct; 19(20):2797-810. PubMed ID: 11033576 [TBL] [Abstract][Full Text] [Related]
73. Updates of bioequivalence programs (including statistical power approximated by Student's t). Wijnand HP Comput Methods Programs Biomed; 1994 Apr; 42(4):275-81. PubMed ID: 7924274 [TBL] [Abstract][Full Text] [Related]
74. A new statistical procedure of interval hypothesis testing for bioequivalence studies. Ohki T; Suzuki T; Goto S Biol Pharm Bull; 1995 Jan; 18(1):192-4. PubMed ID: 7735242 [TBL] [Abstract][Full Text] [Related]
75. Total deviation index for measuring individual agreement with applications in laboratory performance and bioequivalence. Lin LI Stat Med; 2000 Jan; 19(2):255-70. PubMed ID: 10641028 [TBL] [Abstract][Full Text] [Related]
76. Review of methods and criteria for the evaluation of bioequivalence studies. Pabst G; Jaeger H Eur J Clin Pharmacol; 1990; 38(1):5-10. PubMed ID: 2184041 [TBL] [Abstract][Full Text] [Related]
77. Statistical simulation study of new proposed uniformity requirement for bioequivalency studies. Haynes JD J Pharm Sci; 1981 Jun; 70(6):673-5. PubMed ID: 7252814 [TBL] [Abstract][Full Text] [Related]